Clinical trials: Chronic Obstruct Airways Disease
Pulmonary Disease, Chronic Obstructive
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431274
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 239 sites in United States, Argentina and 23 more
- Volunteers
- 2,624 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323621
- Testing
- Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Salbutamol as needed
- Where
- 51 sites in United States, Germany and 4 more
- Volunteers
- 512 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Single Ascending Dose Study of TRN-157 in Healthy Subjects
This single ascending dose study is to determine and evaluate the safety and tolerability of TRN-157 in approximately 40 healthy subjects.
- Trial name
- NCT02133339
- Testing
- TRN-157
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Theron Pharmaceuticals, Inc.
Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
- Trial name
- FRONTIER-4 (NCT04631016)
- Testing
- Tozorakimab
- Where
- 90 sites in United States, Australia and 13 more
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, COPD
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 \& 600 µg o.d.) in order to select two doses to carry forward into study Stage 2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00463567
- Testing
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.)
- Where
- 344 sites in United States, Argentina and 10 more
- Volunteers
- 2,059 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of…
- Trial name
- NCT00106821
- Testing
- Tiotropium Bromide Inhalation Powder
- Where
- 19 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Prednisolone will be used as a model medication to identify new clinical outcomes for future evaluation of new therapies in short-term studies (up to 4 weeks) in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00379730
- Testing
- Prednisolone
- Where
- 5 sites in Argentina, Chile and 2 more
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
COPD (Chronic Obstructive Pulmonary Disease)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD
The goal of this clinical trial is to learn if drug JKN2403 works to treat moderate-to-severe COPD in adults. It will also learn about the safety and pharmacokinetic characteristics of drug JKN2403.
- Trial name
- COPD (NCT07351734)
- Testing
- JKN2403 Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive)…
- Trial name
- PERSEPHONE (NCT07190209)
- Testing
- Lunsekimig
- Where
- 314 sites in United States, Argentina and 23 more
- Volunteers
- 942 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at data from people with chronic obstructive pulmonary disease (COPD). Some used Stiolto Respimat and the others Trelegy Ellipta as their first treatment for COPD.
- Trial name
- NCT05169424
- Testing
- Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg)
- Where
- United States
- Volunteers
- 9,117 people
- Sponsor
- Boehringer Ingelheim
Respiratory Disease, Asthma
Digital App for Telerehabilitation in Respiratory Diseases
The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases.
- Conditions
- Respiratory Disease, Asthma, Long COVID, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05572346
- Testing
- Home-based telerehabilitation program delivered through digital devices
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- MedicAir Healthcare S.r.l.
Emphysema, Chronic Obstructive Pulmonary Disease
Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction
To assess the safety and efficacy of BTVA for the treatment of patients with heterogeneous upper lobe emphysema.
- Trial name
- BTVA (NCT01041586)
- Testing
- BTVA System
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Uptake Medical Corp
COPD, Smoking
Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.
The purpose of this study is to demonstrate the slowing of the disease progression including the improvement of Chronic Obstructive Pulmonary Disease (COPD) symptoms in smoking subjects with mild to moderate COPD and a history of…
- Conditions
- COPD, Smoking, Tobacco Use
- Trial name
- NCT05569005
- Testing
- THS use, Cigarette, Smoking Abstinence
- Where
- 170 sites in United States, Bulgaria and 6 more
- Volunteers
- 715 people
- Sponsor
- Philip Morris Products S.A.
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic
In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency
The Breathe NIOV™ System will reduce the work of breathing in subjects with chronic respiratory insufficiency who require long-term oxygen therapy (LTOT).
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
- Trial name
- NCT01347931
- Testing
- NIOV System, Standard Oxygen Cannula
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Breathe Technologies, Inc.
Pulmonary Disease, Chronic Obstructive
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The safety, tolerability, pharmacokinetics and pharmacodynamics/efficacy profiles of two different doses of GSK233705 will be compared with 2 active comparators and placebo, all medication delivered via dry powder inhaler.
- Trial name
- NCT00422604
- Testing
- salmeterol, tiotropium, GSK233705
- Where
- 11 sites in Finland, Germany and 3 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
The purpose of this study is to evaluate the efficacy and safety of the FSC HFA MDI in subjects with COPD. The dose of FSC HFA MDI to be evaluated corresponds to the dose of FSC DISKUS (250/50mcg twice-daily) that is indicated…
- Trial name
- NCT00633217
- Testing
- Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
- Where
- 16 sites in United States
- Volunteers
- 247 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Infections, Bacterial
Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)
The aim of the study is to develop a new patient-reported outcome (PRO) questionnaire measuring the impact of an acute exacerbation on daily lives of patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00259909
- Testing
- GSK questionnaire, St. George's Respiratory Questionnaire, Acute Short Form 12 version 2
- Where
- 123 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive
- Trial name
- AERODUO-2 (NCT07896252)
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- 2 sites in United Kingdom
- Volunteers
- 64 people
- Sponsor
- AeroRx Therapeutics Inc.
Chronic Obstructive Pulmonary Disease
Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness
The purpose of this study is to show bioequivalence of test product to reference product based on baseline-adjusted forced expiratory volume in one second (FEV1).
- Trial name
- NCT03137992
- Testing
- Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
- Where
- 34 sites in United States
- Volunteers
- 377 people
- Sponsor
- Lupin, Inc.
Pulmonary Disease, Chronic Obstructive
Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease
This is an exploratory study to further develop an imaging platform for the assessment of whole lung neutrophil retention. The primary objective of the study is to quantify and compare neutrophil retention in the lungs of…
- Trial name
- NCT02551614
- Testing
- Lipopolysaccharide challenge, Saline challenge, Labelled neutrophils and Imaging assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.